Skip to main content
SpringerLink
Log in

Reliability of Frequently Used Ear, Nose, and Throat Drugs During Pregnancy and the Postpartum Period

  • Chapter
  • First Online:
ENT Diseases: Diagnosis and Treatment during Pregnancy and Lactation

Abstract

Drug use during pregnancy is a process that may cause adverse effects on both pregnant women and fetuses, but the risk can be reduced by certain precautions. During pregnancy, women can use drugs for various acute or chronic reasons. Although the frequency of drug use during pregnancy may differ between countries, recent studies have shown that the rate of pregnant women using at least one drug during pregnancy is over 50% [1–4]. In a retrospective study (between the years 2008 and 2012), it has been shown that a considerable number of pregnant women used more than one drug, an average of 4,6 medications, in their pregnancy period, excluding vitamins and minerals. [1]. In a multinational study, the frequency of different drug types used in pregnancy has been investigated. While the frequency of drug use for the treatment of acute/short-term illnesses occurred is 68.4%, the frequency of drug use for the treatment of chronic/long-term illnesses occurred is 17%. Over-the-counter (OTC) drug use had a similar frequency with short-term drug use [2]. In another cohort study, it has been demonstrated that the prescription rate for drugs used for pregnancy-related symptoms increased, whereas the prescription rate for drugs used for chronic diseases and for short-time use declined during pregnancy [3]. Physiological variations during pregnancy alter the pharmacokinetics (absorption, distribution, metabolism, elimination) and pharmacodynamics of drugs [5]. Many pharmaceutical clinical experiments are performed on men or non-pregnant women due to ethical considerations and fetal risk. Prediction of the effect, side effect, and fetal risks of drug use in pregnancy is quite complicated due to both maternal pharmacokinetic/pharmacodynamic alterations and limited clinical data.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ventura M, Maraschini A, D’Aloja P, et al. Drug prescribing during pregnancy in a central region of Italy, 2008-2012. BMC Public Health. 2018;18:623. https://doi.org/10.1186/s12889-018-5545-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Lupattelli A, Spigset O, Twigg MJ, et al. Medication use in pregnancy: a cross-sectional, multinational web-based study. BMJ Open. 2014;4(2):e004365. https://doi.org/10.1136/bmjopen-2013-004365.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Bakker MK, Jentink J, Vroom F. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG. 2006;113(5):559–68. https://doi.org/10.1111/j.1471-0528.2006.00927.x.

    Article  CAS  PubMed  Google Scholar 

  4. Mitchell AA, Gilboa SM, Werler MM. National birth defects prevention study. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol. 2011;205(1):51.e1–8. https://doi.org/10.1016/j.ajog.2011.02.029.

    Article  Google Scholar 

  5. Ansari J, Carvalho B, Shafer SL, et al. Pharmacokinetics and pharmacodynamics of drugs commonly used in pregnancy and parturition. Anesth. 2016;122(3):786–804. https://doi.org/10.1213/ANE.0000000000001143.

    Article  CAS  Google Scholar 

  6. Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. Semin Perinatol. 2015;39(7):512–9.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Pavek P, Ceckova M, Staud F. Variation of drug kinetics in pregnancy. Curr Drug Metab. 2009;10(5):520–9. https://doi.org/10.2174/138920009788897993.

    Article  CAS  PubMed  Google Scholar 

  8. Katzung BG. Basic and clinical pharmacology. 14th ed. New York: The McGraw-Hill Companies; 2018.

    Google Scholar 

  9. Tetro N, Moushaev S, Rubinchik-Stern M, et al. The placental barrier: the gate and the fate in drug distribution. Pharm Res. 2018;35(4):71. https://doi.org/10.1007/s11095-017-2286-0.

    Article  CAS  PubMed  Google Scholar 

  10. Koren G, Pariente G. Pregnancy-associated changes in pharmacokinetics and their clinical implications. Pharm Res. 2018;35(3):61. https://doi.org/10.1007/s11095-018-2352-2.

    Article  CAS  PubMed  Google Scholar 

  11. WHO. Congenital anomalies; 2020. https://www.who.int. Accessed 13 July 2020

  12. FDA. Pregnancy and lactation labeling final rule; 2014. https://www.fda.gov. Accessed 20 July 2020

  13. Matsui D. Adherence with drug therapy in pregnancy. Obstet Gynecol Int. 2012;2012:796590. https://doi.org/10.1155/2012/796590.

    Article  PubMed  Google Scholar 

  14. Olesen C, Søndergaard C, Thrane N, et al. Do pregnant women report use of dispensed medications? Epidemiology. 2001;12(5):497–501. https://doi.org/10.1097/00001648-200109000-.

    Article  CAS  PubMed  Google Scholar 

  15. de Jonge L, de Walle HE, de Jong-van den Berg LT, et al. Actual use of medications prescribed during pregnancy: a cross-sectional study using data from a population-based congenital anomaly registry. Drug Saf. 2015;38(8):737–47. https://doi.org/10.1007/s40264-015-0302-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kayhan Tetik B, Gedik Tekinemre I. Emziren annelerde ilaç kullanımı. Jour Turk Fam Phy. 2017;8(3):83–9. (in Turkish). https://doi.org/10.15511/tjtfp.17.00383.

    Article  Google Scholar 

  17. Akkoca AN, Özler GS, Keskin Kurt R, et al. Ear, nose and throat changes observed during three trimester of pregnancy. Sci J Clin Med. 2014;3(3):52–6.

    Google Scholar 

  18. Mgbe RB, Umana AN, Adekanye AG. Ear nose and throat changes observed in pregnancy in Calabar-Nigeria. Offiong Global J Pure Appl Sci. 2017;23:355–9. https://doi.org/10.4314/gjpas.v23i2.16.

    Article  Google Scholar 

  19. Schmidt PM, Flores Fda T, Rossi AG, et al. Hearing and vestibular complaints during pregnancy. Braz J Otorhinolaryngol. 2010;76(1):29–33.

    Article  PubMed  Google Scholar 

  20. Bhagat DR, Chowdhary A, Verma S, et al. Physiological changes in ENT during pregnancy. Indian J Otolaryngol Head Neck Surg. 2006;58(3):268–70. https://doi.org/10.1007/BF03050836.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Stanley AY, Durham CO, Sterrett JJ, et al. Safety of over-the-counter medications in pregnancy. MCN Am J Matern Child Nurs. 2019;44(4):196–205. https://doi.org/10.1097/NMC.0000000000000537.

    Article  PubMed  Google Scholar 

  22. Kayaalp SO. Akılcıl Tedavi Yönünden Tıbbi Farmakoloji, 13. Basım. Pelikan Kitapevi, Ankara; 2018 (ın Turkish).

    Google Scholar 

  23. Bookstaver PB, Bland CM, Griffin B, et al. Review of antibiotic use in pregnancy. Pharmacotherapy. 2015;35(11):1052–62.

    Article  CAS  PubMed  Google Scholar 

  24. Briggs GG, Freeman RK. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 11th ed. Philadelphia: Lippincott Williams & Wilkins; 2007.

    Google Scholar 

  25. Crider KS, Cleves MA, Reefhuis J, et al. Antibacterial medication use during pregnancy and risk of birth defects: national birth defects prevention study. Arch Pediatr Adolesc Med. 2009;11:978–85. https://doi.org/10.1001/archpediatrics.2009.188.

    Article  Google Scholar 

  26. Mungan MT. Gebelikte Antibiyotik Kullanımı. Turkiye Klinikleri J Gynecol Obst. 2001;11(6):451–60. (in Turkish)

    Google Scholar 

  27. Guinto VT, De Guia B, Festin MR, et al. Different antibiotic regimens for treating asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev. 2010;8(9):CD007855. https://doi.org/10.1002/14651858.CD007855.pub2.

    Article  Google Scholar 

  28. Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. CMAJ. 2017;189(17):E625–33. https://doi.org/10.1503/cmaj.161020.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Bush K, Bradford PA. β-lactams and β-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016;6(8):a025247. https://doi.org/10.1101/cshperspect.a025247.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Khanna NR, Gerriets V. Beta lactamase inhibitors. StatPearls [Internet], Treasure Island, FL; 2020. https://www.ncbi.nlm.nih.gov/books/NBK557592/

  31. Lee QU. Use of cephalosporins in patients with immediate penicillin hypersensitivity: cross reactivity revisited. Hong Kong Med J. 2014;20:428–36.

    Article  CAS  PubMed  Google Scholar 

  32. Blaskovich MAT, Hansford KA, Butler MS, et al. Developments in glycopeptide antibiotics. ACS Infect Dis. 2018;4(5):715–35. https://doi.org/10.1021/acsinfecdis.7b00258.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Reyes MP, Ostrea EM Jr, Cabinian AE, et al. Vancomycin during pregnancy: does it cause hearing loss or nephrotoxicity in the infant? Am J Obstet Gynecol. 1989;161(4):977–81.

    Article  CAS  PubMed  Google Scholar 

  34. Dijkmans AC, Zacarías NVO, Burggraaf J, et al. Fosfomycin: pharmacological, clinical and future perspectives. Antibiotics (Basel). 2017;6(4):24.

    Article  CAS  Google Scholar 

  35. Trimble MJ, Mlynárčik P, Kolář M, et al. Polymyxin: alternative mechanisms of action and resistance. Cold Spring Harb Perspect Med. 2016;6(10):a025288. https://doi.org/10.1101/cshperspect.a025288.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Roemer H, Martinez, MT, Katz VL, et al. ENT issues in pregnancy; 2013. https://www.acepnow.com/article/ent-issues-pregnancy/

  37. Dinos GP. The macrolide antibiotic renaissance. Br J Pharmacol. 2017;174:2967–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Seifert R. Basic knowledge of pharmacology. Switzerland: Springer; 2019.

    Book  Google Scholar 

  39. Bulska M, Szcześniak P, Pięta-Dolińska A, et al. The placental transfer of erythromycin in human pregnancies with group B streptococcal infection. Ginekol Pol. 2015;86(1):33–9. https://doi.org/10.17772/gp/1896.

    Article  PubMed  Google Scholar 

  40. Heikkinen T, Laine K, Neuvonen PJ, et al. The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. BJOG. 2000;107(6):770–5. https://doi.org/10.1111/j.1471-0528.2000.tb13339.x.

    Article  CAS  PubMed  Google Scholar 

  41. Bahat Dinur A, Koren G, Matok I, et al. Fetal safety of macrolides. Antimicrob Agents Chemother. 2013;57(7):3307–11. https://doi.org/10.1128/AAC.01691-12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Källén BAJ, Olausson PO. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol. 2003;17(3):255–61.

    Article  PubMed  CAS  Google Scholar 

  43. Albert RK, Schuller JL. COPD clinical research network. Macrolide antibiotics and the risk of cardiac arrhythmias. Am J Respir Crit Care Med. 2014;189(10):1173–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Patel PH, Hashmi MF. Macrolides. StatPearls [Internet], Treasure Island, FL; 2020. https://www.ncbi.nlm.nih.gov/books/NBK551495/

  45. Woodhead JL, Yang K, Oldach D, et al. Analyzing the mechanisms behind macrolide antibiotic-induced liver injury using quantitative systems toxicology modeling. Pharm Res. 2019;36(3):48. https://doi.org/10.1007/s11095-019-2582-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Fernandes P, Martens E, Pereira D. Nature nurtures the design of new semi-synthetic macrolide antibiotics. J Antibiot. 2017;70(5):527–33. https://doi.org/10.1038/ja.2016.137.

    Article  CAS  Google Scholar 

  47. Smieja M. Current indications for the use of clindamycin: a critical review. Can J Infect Dis. 1998;9(1):22–8. https://doi.org/10.1155/1998/538090.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Avent ML, Rogers BA, Cheng AC. Current use of aminoglycosides: Indications, pharmacokinetics and monitoring for toxicity. Intern Med J. 2011;41:441–9.

    Article  CAS  PubMed  Google Scholar 

  49. Krause KM, Serio AW, Kane TR, et al. Aminoglycosides: an overview. Cold Spring Harb Perspect Med. 2016;6(6):a027029. https://doi.org/10.1101/cshperspect.a027029.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. McWilliams CJ, Smith CH, Goldman RD. Acute otitis externa in children. Can Fam Physician. 2012;58(11):1222–4.

    PubMed  PubMed Central  Google Scholar 

  51. Heikkila AM. Antibiotics in pregnancy—a prospective cohort study on the policy of antibiotic prescription. Ann Med. 1993;5:467–71.

    Article  Google Scholar 

  52. Sharma CP, Jain A, Jain S. Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta Poloniae Pharmaceutica ñ Drug Research. 2009;66(6):587–604.

    CAS  Google Scholar 

  53. Wall GM, Stroman DW, Roland PS, et al. Ciprofloxacin 0.3%/dexamethasone 0.1% sterile Otic suspension for the topical treatment of ear infections: a review of the literature. Pediatr Infect Dis J. 2009;28(2):141–4. https://doi.org/10.1097/INF.0b013e31818b0c9c.

    Article  PubMed  Google Scholar 

  54. Acuin J, Smith A, Mackenzie I. Interventions for chronic suppurative otitis media. Cochrane Database Syst Rev. 2000;(2):CD000473. https://doi.org/10.1002/14651858.CD000473.

  55. Yefet E, Schwartz N, Chazan B. The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis. BJOG. 2018;125(9):1069–76. https://doi.org/10.1111/1471-0528.15119.

    Article  CAS  PubMed  Google Scholar 

  56. de Clercq E. Molecular targets for antiviral agents. J Pharmacol Exp Therap. 2001;297(1):1–10.

    Google Scholar 

  57. Paintsil E, Cheng YC. Antiviral agents. Encyclopedia Microbiol. 2009;2009:223–57. https://doi.org/10.1016/B978-012373944-5.00178-4.

    Article  Google Scholar 

  58. Chaudhuri S, Symons JA, Deval J, et al. Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond. Antiviral Res. 2018;155:76–88. https://doi.org/10.1016/j.antiviral.2018.05.005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Louie JK, Acosta M, Jamieson DJ. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med. 2010;362:27–35.

    Article  CAS  PubMed  Google Scholar 

  60. Qiu S, Shen Y, Pan H, et al. Effectiveness and safety of oseltamivir for treating influenza: an updated meta-analysis of clinical trials. Infect Dis (Lond). 2015;47(11):808–19. https://doi.org/10.3109/23744235.2015.1067369.

    Article  CAS  Google Scholar 

  61. Hayashi M, Yamane R, Tanaka M, et al. Pregnancy outcome after maternal exposure to oseltamivir phosphate during the first trimester: a case series survey [Japanese]. Nihon Byoin Yakuzaishi Gakkai Zasshi. 2009;45:547–50.

    Google Scholar 

  62. Meijer WJ, van Noortwijk AG, Bruinse HW, et al. Influenza virus infection in pregnancy: a review. Acta Obstet Gynecol Scand. 2015;94(8):797–819. https://doi.org/10.1111/aogs.12680.

    Article  PubMed  Google Scholar 

  63. Graner S, Svensson T, Beau AB, et al. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study. BMJ. 2017;356:j629. https://doi.org/10.1136/bmj.j629.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Svensson T, Granath F, Stephansson O. Birth outcomes among women exposed to neuraminidase inhibitors during pregnancy. Pharmacoepidemiol Drug Saf. 2011;20(10):1030–4. https://doi.org/10.1002/pds.2194.

    Article  CAS  PubMed  Google Scholar 

  65. Wentges-van Holthe N, van Eijkeren M, van der Laan JW. Oseltamivir and breast-feeding. Int J Infect Dis. 2008;12:451.

    Article  PubMed  Google Scholar 

  66. Ison MG. Clinical use of approved influenza antivirals: therapy and prophylaxis. Influenza Other Respir Viruses. 2013;7(Suppl 1):7–13. https://doi.org/10.1111/irv.12046.

    Article  CAS  PubMed  Google Scholar 

  67. Morris DJ. Adverse effects and drug interactions of clinical importance with antiviral drugs. Drug Saf. 1994;10(4):281–91. https://doi.org/10.2165/00002018-199410040-00002.

    Article  CAS  PubMed  Google Scholar 

  68. Eviston TJ, Croxson G, Kennedy PGE, et al. Bell’s palsy: aetiology, clinical features and multidisciplinary care. J Neurol Neurosurg Psychiatry. 2015;86:1356–61.

    Article  PubMed  Google Scholar 

  69. Hussain A, Charles Nduka C, Moth P, et al. Bell’s facial nerve palsy in pregnancy: a clinical review. J Obstet Gynaecol. 2017;37(4):409–15.

    Article  PubMed  Google Scholar 

  70. Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA. 2010;304(8):859–66. https://doi.org/10.1001/jama.2010.1206.

    Article  CAS  PubMed  Google Scholar 

  71. Anwar K, Gohar MS. Otomycosis; clinical features, predisposing factors and treatment implications. Pak J Med Sci. 2014;30(3):564–7. https://doi.org/10.12669/pjms.303.4106.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Vennewald I, Klemm E. Otomycosis: diagnosis and treatment. Clin Dermatol. 2010;28:202–11.

    Article  PubMed  Google Scholar 

  73. Moudgal VV, Sobel JD. Antifungal drugs in pregnancy: a review. Expert Opin Drug Saf. 2003;2(5):475–83.

    Article  CAS  PubMed  Google Scholar 

  74. Thompson GR III, Patterson TF. Mycosis of the maxillary fungal disease of the nose and paranasal sinuses. J Allergy Clin Immunol. 2012;129(2):321–6.

    Article  PubMed  Google Scholar 

  75. Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg. 2015;152(1 Suppl):S1–S43. https://doi.org/10.1177/0194599814561600.

    Article  PubMed  Google Scholar 

  76. Caparroz FA, Gregorio LL, Bongiovanni G, et al. Rhinitis and pregnancy: literature review. Braz J Otorhinolaryngol. 2016;82(1):105–11. https://doi.org/10.1016/j.bjorl.2015.04.011.

    Article  PubMed  Google Scholar 

  77. Ellegård EK. Clinical and pathogenetic characteristics of pregnancy rhinitis. Clinic Rev Allerg Immunol. 2004;26:149–59. https://doi.org/10.1385/CRIAI:26:3:149.

    Article  Google Scholar 

  78. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy. 2008;63(10):1292–300. https://doi.org/10.1111/j.1398-9995.2008.01750.x.

    Article  CAS  PubMed  Google Scholar 

  79. Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012;22(1):1–12.

    CAS  PubMed  Google Scholar 

  80. NHS, Hull & East Riding Prescribing Committee. Prescribing guideline for rhinitis; 2020. https://www.hey.nhs.uk. Accessed 13 July 2020

  81. Alhussien AH, Alhedaithy RA, Alsaleh SA. Safety of intranasal corticosteroid sprays during pregnancy: an updated review. Eur Arch Otorhinolaryngol. 2018;275(2):325–33. https://doi.org/10.1007/s00405-017-4785-3.

    Article  PubMed  Google Scholar 

  82. Ridolo E, Caminati M, Martignago I, et al. Allergic rhinitis: pharmacotherapy in pregnancy and old age. Expert Rev Clin Pharmacol. 2016;9(8):1081–9. https://doi.org/10.1080/17512433.2016.1189324.

    Article  CAS  PubMed  Google Scholar 

  83. Keles N. Treatment of allergic rhinitis during pregnancy. Am J Rhinol. 2004;18(1):23–8.

    Article  PubMed  Google Scholar 

  84. Mazzotta P, Loebstein R, Koren G. Treating allergic rhinitis in pregnancy. Safety considerations. Drug Saf. 1999;20(4):361–75. https://doi.org/10.2165/00002018-199920040-00005.

    Article  CAS  PubMed  Google Scholar 

  85. Drugs and Lactation Database (LactMed). Mometasone, nasal; 2020. https://www.ncbi.nlm.nih.gov. Accessed 13 July 2020

  86. Cobanoglu B, Toskala E, Ural E, et al. Role of leukotriene antagonists and antihistamines in the treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2013;13:203–8.

    Article  CAS  PubMed  Google Scholar 

  87. Hoecke HV, Vandenbulcke L, Van Cauwenberge P. Histamine and leukotriene receptor antagonism in the treatment of allergic rhinitis. Drugs. 2007;67(18):2717–26.

    Article  PubMed  Google Scholar 

  88. Church MK, Church DS. Pharmacology of antihistamines. Indian J Dermatol. 2013;58(3):219–24. https://doi.org/10.4103/0019-5154.110832.

    Article  PubMed  PubMed Central  Google Scholar 

  89. McParlin C, O’Donnell A, Robson SC, et al. Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: a systematic review. JAMA. 2016;316(13):1392–401. https://doi.org/10.1001/jama.2016.14337.

    Article  PubMed  Google Scholar 

  90. Poluzzi E, Diemberger I, De Ridder M, et al. Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countriesfrom the ARITMO project. Eur J Clin Pharmacol. 2017;73:1499–510.

    Article  CAS  PubMed  Google Scholar 

  91. Gilbert C, Mazzotta P, Loebstein R, et al. Fetal safety of drugs used in the treatment of allergic rhinitis. Drug-Safety. 2005;28:707–19.

    Article  CAS  PubMed  Google Scholar 

  92. Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. Am J Perinatol. 1997;14(3):119–24. https://doi.org/10.1055/s-2007-994110.

    Article  CAS  PubMed  Google Scholar 

  93. Kar S, Ajay Krishnan A, Preetha K. A review of antihistamines used during pregnancy. J Pharmacol Pharmacother. 2012;3(2):105–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  94. Pali-Schöll I, Namazy J, Jensen-Jarolim E. Allergic diseases and asthma in pregnancy, a secondary publication. World Allergy Organ J. 2017;10(1):10. https://doi.org/10.1186/s40413-017-0141-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review. Clin Pharmacokinet. 2008;47(4):217–30. https://doi.org/10.2165/00003088-200847040-00001.

    Article  CAS  PubMed  Google Scholar 

  96. Golembesky A, Cooney M, Boev R, et al. Safety of cetirizine in pregnancy. J Obstet Gynaecol. 2018;38(7):940–5. https://doi.org/10.1080/01443615.2018.1441271.

    Article  CAS  PubMed  Google Scholar 

  97. Wang XY, Lim-Jurado M, Prepageran N, et al. Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine. Ther Clin Risk Manag. 2016;12:585–97. https://doi.org/10.2147/TCRM.S105189.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Andersson NW, Torp-Pedersen C, Andersen JT. Association between fexofenadine use during pregnancy and fetal outcomes. JAMA Pediatr. 2020;174(8):e201316. https://doi.org/10.1001/jamapediatrics.2020.1316.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Salib RJ, Howarth PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf. 2003;26(12):863–93. https://doi.org/10.2165/00002018-200326120-00003.

    Article  CAS  PubMed  Google Scholar 

  100. Namazy J, Schatz M. The treatment of allergic respiratory disease during pregnancy. J Investig Allergol Clin Immunol. 2016;26(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  101. Lipworth BJ. Leukotriene-receptor antagonists. Lancet. 1999;353(9146):57–62. https://doi.org/10.1016/S0140-6736(98)09019-9.

    Article  CAS  PubMed  Google Scholar 

  102. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med. 2004;116(5):338–44. https://doi.org/10.1016/j.amjmed.2003.10.030.

    Article  CAS  PubMed  Google Scholar 

  103. Choi J, Azmat CE. Leukotriene receptor antagonists. StatPearls [Internet], Treasure Island, FL; 2020. https://www.ncbi.nlm.nih.gov/books/NBK554445/

  104. Wang H, Li N, Huang H. Asthma in pregnancy: pathophysiology, diagnosis, whole-course management, and medication safety. Can Respir J. 2020; https://doi.org/10.1155/2020/9046842.

  105. Cavero-Carbonell C, Vinkel-Hansen A, Rabanque-Hernández MJ, et al. Fetal exposure to montelukast and congenital anomalies: a population based study in Denmark. Birth Defects Res. 2017;109(6):452–9. https://doi.org/10.1002/bdra.23621.

    Article  CAS  PubMed  Google Scholar 

  106. Bakhireva LN, Jones KL, Schatz M, et al. Safety of leukotriene receptor antagonists in pregnancy. J Allergy Clin Immunol. 2007;119(3):618–25. https://doi.org/10.1016/j.jaci.2006.12.618.

    Article  CAS  PubMed  Google Scholar 

  107. Tamada T, Ichinose M. Leukotriene receptor antagonists and antiallergy drugs. In: Page C, Barnes P, editors. Pharmacology and therapeutics of asthma and COPD. Handbook of experimental pharmacology, vol 237. Switzerland: Springer; 2016. https://doi.org/10.1007/164_2016_72.

    Chapter  Google Scholar 

  108. Gluck JC, Gluck PA. Asthma controller therapy during pregnancy. Am J Obstet Gynecol. 2005;192(2):369–80. https://doi.org/10.1016/j.ajog.2004.07.056.

    Article  PubMed  Google Scholar 

  109. Wahid NWB, Shermetaro C. Rhinitis Medicamentosa. StatPearls [Internet], Treasure Island, FL; 2020. https://www.ncbi.nlm.nih.gov/books/NBK538318/.

  110. Passàli D, Salerni L, Passàli GC, et al. Nasal decongestants in the treatment of chronic nasal obstruction: efficacy and safety of use. Expert Opin Drug Saf. 2006;5(6):783–90. https://doi.org/10.1517/14740338.5.6.783.

    Article  PubMed  Google Scholar 

  111. Gonzalez-Estrada A, Geraci SA. Allergy medications during pregnancy. Am J Med Sci. 2016;352(3):326–31. https://doi.org/10.1016/j.amjms.2016.05.030.

    Article  PubMed  Google Scholar 

  112. Torfs CP, Katz EA, Bateson TF, et al. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology. 1996;54(2):84–92. https://doi.org/10.1002/(SICI)1096-9926(199606)54:2<84::AID-TERA4>3.0.CO;2-4.

    Article  CAS  PubMed  Google Scholar 

  113. Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology. 1992;45(4):361–7. https://doi.org/10.1002/tera.1420450407.

    Article  CAS  PubMed  Google Scholar 

  114. Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol. 2002;155(1):26–31. https://doi.org/10.1093/aje/155.1.26.

    Article  PubMed  Google Scholar 

  115. Aljazaf K, Hale TW, Ilett KF, et al. Pseudoephedrine: effects on milk production in women and estimation of infant exposure via breastmilk. Br J Clin Pharmacol. 2003;56(1):18–24. https://doi.org/10.1046/j.1365-2125.2003.01822.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Bandoli G, Palmsten K, Forbess Smith CJ, et al. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin North Am. 2017;43(3):489–502. https://doi.org/10.1016/j.rdc.2017.04.013.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Vlastarakos PV, Nikolopoulos TP, Manolopoulos L. Treating common ear problems in pregnancy: what is safe? Eur Arch Otorhinolaryngol. 2008;265(2):139–45. https://doi.org/10.1007/s00405-007-0534-3.

    Article  PubMed  Google Scholar 

  118. Källén BAJ. Maternal drug use and infant cleft lip/palate with special reference to corticoids. Cleft Palate Craniofac J. 2003;40(6):624–8. https://doi.org/10.1597/02-077.

    Article  PubMed  Google Scholar 

  119. Bjørn AM, Ehrenstein V, Nohr EA, et al. Use of inhaled and oral corticosteroids in pregnancy and the risk of malformations or miscarriage. Basic Clin Pharmacol Toxicol. 2015;116(4):308–14. https://doi.org/10.1111/bcpt.12367.

    Article  CAS  PubMed  Google Scholar 

  120. Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ. 2011;183(7):796–804. https://doi.org/10.1503/cmaj.101063.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Powrie RO, Larson L, Miller M. Managing asthma in expectant mothers. Treat Respir Med. 2006;5(1):1–10. https://doi.org/10.2165/00151829-200605010-00001.

    Article  CAS  PubMed  Google Scholar 

  122. El-Qutob D. Off-label uses of omalizumab. Clinic Rev Allerg Immunol. 2016;50:84–96.

    Article  CAS  Google Scholar 

  123. Tsabouri S, Tseretopoulou X, Priftis K, et al. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract. 2014;2(3):332–40. https://doi.org/10.1016/j.jaip.2014.02.001.

    Article  PubMed  Google Scholar 

  124. Kelly W, Massoumi A, Lazarus A. Asthma in pregnancy: physiology, diagnosis, and management. Postgrad Med. 2015;127(4):349–58. https://doi.org/10.1080/00325481.2015.1016386.

    Article  PubMed  Google Scholar 

  125. Namazy J, Cabana MD, Scheuerle AE, et al. The Xolair pregnancy registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol. 2015;135(2):407–12. https://doi.org/10.1016/j.jaci.2014.08.025.

    Article  CAS  PubMed  Google Scholar 

  126. Labrador-Horrillo M, Ferrer M. Profile of omalizumab in the treatment of chronic spontaneous urticaria. Drug Design Dev Ther. 2015;9:4909–15.

    Article  CAS  Google Scholar 

  127. Pakes GE, Brogden RN, Heel RC, et al. Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis. Drugs. 1980;20(4):237–66. https://doi.org/10.2165/00003495-198020040-00001.

    Article  CAS  PubMed  Google Scholar 

  128. Sur DKC, Plesa ML. Chronic nonallergic rhinitis. Am Fam Physician. 2018;98(3):171–6.

    PubMed  Google Scholar 

  129. Niggeschulze A, Palmer AK. Reproduktionstoxikologische Untersuchungen mit Ipratropiumbromid [Reproductive toxicological investigations with ipratropiumbromide (author’s transl)]. Arzneimittelforschung. 1976;26(5a):989–92.

    CAS  PubMed  Google Scholar 

  130. Egan M, Bunyavanich S. Allergic rhinitis: the “Ghost Diagnosis” in patients with asthma. Asthma Res and Pract. 2015;1:8. https://doi.org/10.1186/s40733-015-0008-0.

    Article  Google Scholar 

  131. Sankaran P, Brockwell C, Wilson A. The effect of theophylline in patients with allergic rhinitis: a double-blind, randomised, crossover study. Eur Respir J. 2014;44:4666.

    Google Scholar 

  132. Basnet RM, Zizioli D, Guarient M, et al. Methylxanthines induce structural and functional alterations of the cardiac system in zebrafish embryos. BMC Pharmacol Toxicol. 2017;18(1):72. https://doi.org/10.1186/s40360-017-0179-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Park BK, Kitteringham NR. Assessment of enzyme induction and enzyme inhibition in humans: toxicological implications. Xenobiotica. 1990;20(11):1171–85. https://doi.org/10.3109/00498259009046837.

    Article  CAS  PubMed  Google Scholar 

  134. Rosa F. Databases in the assessment of the effects of drugs during pregnancy. J Allergy Clin Immunol Pract. 1999;103(2):S360–1. https://doi.org/10.1016/S0091-6749(99)70264-2.

    Article  CAS  Google Scholar 

  135. Stenius-Aarniala BS, Hedman J, Teramo KA. Acute asthma during pregnancy. Thorax. 1996;51(4):411–4. https://doi.org/10.1136/thx.51.4.411.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Schatz M. Asthma treatment during pregnancy what can be safely taken? Drug Safety. 1997;16(5):342–50.

    Article  CAS  PubMed  Google Scholar 

  137. Bonham CA, Patterson KC, Strek ME. Asthma outcomes and management during pregnancy. Chest. 2018;153(2):515–27. https://doi.org/10.1016/j.chest.2017.08.029.

    Article  PubMed  Google Scholar 

  138. Carter BL, Driscoll CE, Smith GD. Theophylline clearance during pregnancy. Obstet Gynecol. 1986;68(4):555–9.

    CAS  PubMed  Google Scholar 

  139. Magnan J, Özgirgin ON, Trabalzini F, et al. European position statement on diagnosis, and treatment of Meniere’s disease. J Int Adv Otol. 2018;14(2):317–21. https://doi.org/10.5152/iao.2018.140818.

    Article  PubMed  PubMed Central  Google Scholar 

  140. Buharalioglu CK, Acar S, Erol-Coskun H, et al. Pregnancy outcomes after maternal betahistine exposure: a case series. Reprod Toxicol. 2018;79:79–83. https://doi.org/10.1016/j.reprotox.2018.06.004.

    Article  CAS  PubMed  Google Scholar 

  141. Babaei AH, Foghaha MH. A randomized comparison of vitamin B6 and dimenhydrinate in the treatment of nausea and vomiting in early pregnancy. Iran J Nurs Midwifery Res. 2014;19(2):199–202.

    PubMed  PubMed Central  Google Scholar 

  142. Shiny Sherlie V, Varghese A. ENT changes of pregnancy and its management. Indian J Otolaryngol Head Neck Surg. 2014;66(Suppl 1):6–9. https://doi.org/10.1007/s12070-011-0376-6.

    Article  CAS  PubMed  Google Scholar 

  143. Boelig RC, Barton SJ, Saccone G, et al. Interventions for treating hyperemesis gravidarum: a Cochrane systematic review and meta-analysis. J Matern Fetal Neonatal Med. 2018;31(18):2492–505. https://doi.org/10.1080/14767058.2017.1342805.

    Article  PubMed  Google Scholar 

  144. Fejzo MS, Trovik J, Grooten IJ, et al. Nausea and vomiting of pregnancy and hyperemesis gravidarum. Nat Rev Dis Primers. 2019;5:62. https://doi.org/10.1038/s41572-019-0110-3.

    Article  PubMed  Google Scholar 

  145. Mazzotta P, Magee LA. A risk-benefit assessment of pharmacological and nonpharmacological treatments for nausea and vomiting of pregnancy. Drugs. 2000;59:781–800. https://doi.org/10.2165/00003495-200059040-00005.

    Article  CAS  PubMed  Google Scholar 

  146. Danielsson B, Webster WS, Ritchie HE. Ondansetron and teratogenicity in rats: evidence for a mechanism mediated via embryonic hERG blockade. Reprod Toxicol. 2018;81:237–45.

    Article  CAS  PubMed  Google Scholar 

  147. Lavecchia M, Chari R, Campbell S, et al. Ondansetron in pregnancy and the risk of congenital malformations: a systematic review. J Obstet Gynaecol Can. 2018;40(7):910–8. https://doi.org/10.1016/j.jogc.2017.10.024.

    Article  PubMed  Google Scholar 

  148. Huybrechts KF, Hernández-Díaz S, Straub L, et al. Association of maternal first-trimester ondansetron use with cardiac malformations and oral clefts in offspring. JAMA. 2018;320(23):2429–37. https://doi.org/10.1001/jama.2018.18307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Murthy JM, Saxena AB. Bell’s palsy: treatment guidelines. Ann Indian Acad Neurol. 2011;14(Suppl 1):S70–2. https://doi.org/10.4103/0972-2327.83092.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  150. Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell’s palsy. N Engl J Med. 2007;357(16):1598–607. https://doi.org/10.1056/NEJMoa072006.

    Article  CAS  PubMed  Google Scholar 

  151. Engström M, Berg T, Stjernquist-Desatnik A, et al. Prednisolone and valaciclovir in Bell’s palsy: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2008;7(11):993–1000. https://doi.org/10.1016/S1474-4422(08)70221-7.

    Article  PubMed  Google Scholar 

  152. Bajalan M, Biggs TC, Jayaram S, et al. A guide to new anticoagulant medications for ENT surgeons. J Laryngol Otol. 2015;129(12):1167–73. https://doi.org/10.1017/S0022215115002765.

    Article  CAS  PubMed  Google Scholar 

  153. Onishi A, St Ange K, Dordick JS, et al. Heparin and anticoagulation. Front Biosci (Landmark Ed). 2016;21:1372–92. https://doi.org/10.1016/j.reprotox.2018.08.018.

    Article  CAS  Google Scholar 

  154. Fogerty AE. Management of venous thromboembolism in pregnancy. Curr Treat Options Cardiovasc Med. 2018;20(8):69. https://doi.org/10.1007/s11936-018-0658-3.

    Article  PubMed  Google Scholar 

  155. Devis P, Knuttinen MG. Deep venous thrombosis in pregnancy: incidence, pathogenesis and endovascular management. Cardiovasc Diagn Ther. 2017;7(Suppl 3):S309–19. https://doi.org/10.21037/cdt.2017.10.08.

    Article  PubMed  PubMed Central  Google Scholar 

  156. Toyoda K. Antithrombotic therapy for pregnant women. Neurol Med Chir (Tokyo). 2013;53(8):526–30. https://doi.org/10.2176/nmc.53.526.

    Article  Google Scholar 

  157. Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41(1):206–32. https://doi.org/10.1007/s11239-015-1310-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  158. Piccioni MG, Derme M, Salerno L, et al. Management of severe epistaxis during pregnancy: a case report and review of the literature. Case Reports Obstet Gynecol. 2019; https://doi.org/10.1155/2019/5825309.

  159. Wu PH, Cheng PW, Young YH. Inner ear disorders in 68 pregnant women: a 20-year experience. Clin Otolaryngol. 2016;42:844–950.

    Article  PubMed  Google Scholar 

  160. Xie S, Wu X. Clinical management and progress in sudden sensorineural hearing loss during pregnancy. J Int Med Res. 2019; https://doi.org/10.1177/0300060519870718.

  161. Conlin AE, Parnes LS. Treatment of sudden sensorineural hearing loss: I. A systematic review. Arch Otolaryngol Head Neck Surg. 2007;133(6):573–81. https://doi.org/10.1001/archotol.133.6.573.

    Article  PubMed  Google Scholar 

  162. Richter JE. Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin North Am. 2003;32(1):235–61. https://doi.org/10.1016/s0889-8553(02)00065-1.

    Article  PubMed  Google Scholar 

  163. Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med. 2010;363(22):2114–23. https://doi.org/10.1056/NEJMoa1002689.

    Article  CAS  PubMed  Google Scholar 

  164. Black E, Khor KE, Kennedy D, et al. Medication use and pain management in pregnancy: a critical review. Pain Pract. 2019;19(8):875–99. https://doi.org/10.1111/papr.12814.

    Article  PubMed  Google Scholar 

  165. Antonucci R, Zaffanello M, Puxeddu E, et al. Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr Drug Metab. 2012;13(4):474–90. https://doi.org/10.2174/138920012800166607.

    Article  CAS  PubMed  Google Scholar 

  166. Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice. Rheumatology (Oxford). 2016;55(9):1698–702. https://doi.org/10.1093/rheumatology/kev405.

    Article  Google Scholar 

  167. Källén B, Reis M. Ongoing pharmacological management of chronic pain in pregnancy. Drugs. 2016;76(9):915–24. https://doi.org/10.1007/s40265-016-0582-3.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Pharmacology, Faculty of Medicine, Lokman Hekim University, Ankara, Turkey

    Elif Hilal Vural

  2. Department of Pharmacology, Gülhane Pharmacy Faculty, Health Sciences University, Ankara, Turkey

    Ismail Mert Vural

Authors
  1. Elif Hilal Vural
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ismail Mert Vural
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elif Hilal Vural .

Editor information

Editors and Affiliations

  1. Department of Otorhinolaryngology, Faculty of Medicine, Eskişehir Osmangazi University, Eskisehir, Turkey

    Cemal Cingi

  2. Department of Otorhinolaryngology, Derince Training and Research Hospital, Faculty of Medicine, Health Sciences University, Kocaeli, Turkey

    Halil Erdem Özel

  3. Department of Otorhinolaryngology, Faculty of Medicine, Kırıkkale University, Kırıkkale, Turkey

    Nuray Bayar Muluk

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Vural, E.H., Vural, I.M. (2022). Reliability of Frequently Used Ear, Nose, and Throat Drugs During Pregnancy and the Postpartum Period. In: Cingi, C., Özel, H.E., Bayar Muluk, N. (eds) ENT Diseases: Diagnosis and Treatment during Pregnancy and Lactation. Springer, Cham. https://doi.org/10.1007/978-3-031-05303-0_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-05303-0_28

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-05302-3

  • Online ISBN: 978-3-031-05303-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation